JP2005509038A - 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤 - Google Patents

多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤 Download PDF

Info

Publication number
JP2005509038A
JP2005509038A JP2003544052A JP2003544052A JP2005509038A JP 2005509038 A JP2005509038 A JP 2005509038A JP 2003544052 A JP2003544052 A JP 2003544052A JP 2003544052 A JP2003544052 A JP 2003544052A JP 2005509038 A JP2005509038 A JP 2005509038A
Authority
JP
Japan
Prior art keywords
group
alkyl
independently
aryl
moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003544052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509038A5 (enExample
Inventor
セオドロス アスベロム，
ジョン ダブリュー． クラダー，
ユエチン フ，
ディミトリ エー． ピッサーニトスキ，
スタムフォード，　アンドリュー　ダブリュー．
ルオ シュー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005509038A publication Critical patent/JP2005509038A/ja
Publication of JP2005509038A5 publication Critical patent/JP2005509038A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003544052A 2001-11-09 2002-11-07 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤 Pending JP2005509038A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34449801P 2001-11-09 2001-11-09
PCT/US2002/035721 WO2003042216A1 (en) 2001-11-09 2002-11-07 Polycyclic guanine derivative phosphodiesterase v inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005306453A Division JP2006077023A (ja) 2001-11-09 2005-10-20 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤

Publications (2)

Publication Number Publication Date
JP2005509038A true JP2005509038A (ja) 2005-04-07
JP2005509038A5 JP2005509038A5 (enExample) 2006-01-05

Family

ID=23350773

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003544052A Pending JP2005509038A (ja) 2001-11-09 2002-11-07 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
JP2005306453A Pending JP2006077023A (ja) 2001-11-09 2005-10-20 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005306453A Pending JP2006077023A (ja) 2001-11-09 2005-10-20 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤

Country Status (7)

Country Link
US (2) US6943171B2 (enExample)
EP (1) EP1442042A1 (enExample)
JP (2) JP2005509038A (enExample)
CN (1) CN1585771A (enExample)
CA (1) CA2465893A1 (enExample)
MX (1) MXPA04004370A (enExample)
WO (1) WO2003042216A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012510993A (ja) * 2008-12-06 2012-05-17 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2014516086A (ja) * 2011-06-10 2014-07-07 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459161A1 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
JP2005513060A (ja) * 2001-12-17 2005-05-12 アルタナ　ファルマ　アクチエンゲゼルシャフト 選択的ｐｄｅ５阻害剤の新規使用
ES2270047T3 (es) * 2002-05-31 2007-04-01 Schering Corporation Proceso para preparar inhibidores de la fosfodiesterasa v de xantina y sus precursores.
EP1719772A1 (en) * 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
TW200526664A (en) * 2003-11-21 2005-08-16 Schering Corp Phosphodiesterase V inhibitor formulation
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
WO2007070426A2 (en) * 2005-12-09 2007-06-21 Mayo Foundation For Medical Education And Research Sexual dysfunction
EP2081431B1 (en) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
KR20130122023A (ko) 2007-02-12 2013-11-06 디엠아이 바이오사이언시스 인코포레이티드 트라마돌의 부작용을 감소시키는 방법
SG174079A1 (en) * 2007-02-12 2011-09-29 Dmi Biosciences Inc Treatment of comorbid premature ejaculation and erectile dysfunction
CA2691194A1 (en) * 2007-06-21 2008-12-31 Deen Tulshian Polycyclic guanine derivatives and methods of use thereof
CN104402893A (zh) 2007-12-06 2015-03-11 武田药品工业株式会社 有机化合物
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
KR20110103949A (ko) 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE-1-HEMMER FOR EYE DRESSING
WO2010132127A1 (en) * 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc NEW REGULATOR PROTEINS AND HEMMER
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
TWI659032B (zh) 2013-03-15 2019-05-11 美商內胞醫療公司 有機化合物及其用途
EP3479825B1 (en) 2013-03-15 2021-02-17 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
JP6591530B2 (ja) 2014-08-07 2019-10-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
IL292225B2 (en) 2014-09-17 2024-12-01 Intra Cellular Therapies Inc Derivatives of 5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one and pharmaceutical compositions comprising them.
CN104262340B (zh) * 2014-09-19 2016-08-31 济南诚汇双达化工有限公司 一种他达拉非的制备方法
AU2015357496B2 (en) 2014-12-06 2019-09-19 Intra-Cellular Therapies, Inc. Organic compounds
KR102562576B1 (ko) 2014-12-06 2023-08-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN105294733A (zh) * 2015-11-02 2016-02-03 上海伊贸斯生物材料有限公司 一种咪唑并噁嗪酮化合物及其制备方法和用途
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
EP3970719A1 (en) 2016-09-12 2022-03-23 Intra-Cellular Therapies, Inc. Pde1 inhibitor for use in a method of treatment or prophylaxis of inflammation and/or an inflammatory disease or disorder
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
MX2021004531A (es) * 2018-10-21 2021-09-10 Intra Cellular Therapies Inc Nuevos usos.
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
KR102336697B1 (ko) * 2019-11-14 2021-12-06 순천향대학교 산학협력단 실데나필 및 rock 저해제를 포함하는 뇌졸중으로 인한 운동 기능 손실의 치료용 약학적 조성물
JP7399284B2 (ja) * 2019-11-14 2023-12-15 スンチョンヒャン ユニバーシティ インダストリー アカデミー コーポレーション ファウンデーション 脳卒中または脳卒中による後遺症治療のためのシルデナフィル及びｒｏｃｋ阻害剤の用途
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2116302A1 (en) 1970-12-07 1972-07-13 Brun Lab Sa Le 8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity
IT1217190B (it) 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
FR2654935B1 (fr) 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
NZ238609A (en) 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
KR930703319A (ko) 1990-12-21 1993-11-29 데이빗 로버츠 키산틴 유도체
US5688768A (en) 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
US5256766A (en) 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
FI953981A7 (fi) * 1993-02-26 1995-08-24 Schering Corp 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9405518D0 (en) * 1994-03-21 1994-05-04 Mupor Ltd Porous metal composite body
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
EP0820441B1 (en) 1995-04-10 2002-06-26 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
IL124969A (en) 1995-12-28 2002-09-12 Fujisawa Pharmaceutical Co History of benzimidazole, processes for their preparation and pharmaceutical preparations containing them
SK154498A3 (en) 1996-05-10 2000-01-18 Icos Corp Carboline derivatives, process for the preparation thereof, pharmaceutical compositions containing same and use of mentioned derivatives as drugs
HUP9900790A3 (en) 1996-08-30 2001-11-28 Kyowa Hakko Kogyo Kk Imidazoquinazoline derivatives
AU4400597A (en) 1996-10-08 1998-05-05 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5874437A (en) 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
AU730670B2 (en) 1997-04-25 2001-03-08 Pfizer Limited Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
TW453999B (en) 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
DE69826286T2 (de) 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
WO1999021831A1 (en) 1997-10-27 1999-05-06 Fujisawa Pharmaceutical Co., Ltd. Tricyclic compounds as cgmp-pde inhibitors
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
JP2003525845A (ja) 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU740758B2 (en) 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
PT1049695E (pt) 1997-11-12 2002-07-31 Bayer Ag Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
EP1057819A4 (en) 1998-02-19 2003-02-05 Eisai Co Ltd PHTALAZINE DERIVATIVES AND REMEDIES FOR DYSERECTION
WO1999043674A1 (en) 1998-02-27 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedies for erectile dysfunction
WO1999043679A1 (en) 1998-02-27 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
PT1371647E (pt) 1998-04-20 2005-10-31 Pfizer Derivados do acido piridina-3-carboxilico e sua utilizacao como intermediarios
AU4501199A (en) 1998-06-03 1999-12-20 Almirall Prodesfarma S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
JP3827875B2 (ja) * 1999-01-27 2006-09-27 アルプス電気株式会社 メンブレンスイッチ
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6969719B2 (en) * 2001-08-28 2005-11-29 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012510993A (ja) * 2008-12-06 2012-05-17 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2014516086A (ja) * 2011-06-10 2014-07-07 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物

Also Published As

Publication number Publication date
CA2465893A1 (en) 2003-05-22
EP1442042A1 (en) 2004-08-04
US6943171B2 (en) 2005-09-13
MXPA04004370A (es) 2004-08-11
JP2006077023A (ja) 2006-03-23
US20050171129A1 (en) 2005-08-04
WO2003042216A1 (en) 2003-05-22
US20030176413A1 (en) 2003-09-18
CN1585771A (zh) 2005-02-23

Similar Documents

Publication Publication Date Title
JP2005509038A (ja) 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
JP4450365B2 (ja) 多環式グアニンホスホジエステラーゼｖ阻害剤
JP4775767B2 (ja) 非芳香環縮合ピリミジン誘導体
KR101661405B1 (ko) 사이클린 의존성 키나제 억제제로서의 신규 피라졸로피리미딘 유도체
JP5710492B2 (ja) 有機化合物
JP5784501B2 (ja) 有機化合物
JP5989993B2 (ja) 有機化合物
JPH0256484A (ja) 縮合ピリミジン誘導体およびその製造方法
KR102332957B1 (ko) 화합물 및 방법
JP2013527236A (ja) 有機化合物
WO2007055418A1 (ja) アザ置換スピロ誘導体
JP2005501122A (ja) 新規４−アミノフロピリミジン化合物およびそれらの使用
CN105884695B (zh) 杂环衍生物类酪氨酸激酶抑制剂
KR20100031610A (ko) 아데노신 Ａ3 수용체 리간드로서의 트리아졸로[1,5-ａ]퀴놀린
US20100305143A1 (en) Pyrrolopyrimidine compounds
CN114656472A (zh) 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
JP2010540422A (ja) チエノピリミジン化合物類
CN109988170A (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN108299436B (zh) 黄嘌呤类化合物及其药物组合物和应用
CN114671875A (zh) 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
JPWO2003020723A1 (ja) ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
TWI602818B (zh) 稠合雜環化合物作爲蛋白激酶抑制劑
TW202540108A (zh) Myt1激酶抑制劑化合物、其藥物組合物及其用途
CN114907406A (zh) 嘧啶衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100129